Human DSG2/CDHF5/HDGC ORF/cDNA clone-Adenovirus particle (NM_001943.5)
Cat. No.: vGMAD001272
Pre-made Human DSG2/CDHF5/HDGC Adenovirus for DSG2 overexpression in-vitro and in-vivo. The DSG2 adenoviral vector excels as a vehicle for transient gene transfection in both stable cell lines and primary cells, including DC cells, macrophages, cardiomyocytes, hepatocytes, and neurons. The purified DSG2-encoding adenovirus also stands out as a quintessential tool for in vivo studies and vaccine research initiatives.
At GM Vector Core (GMVC), we provide bespoke adenovirus development and manufacture various grades of adenoviruses utilizing cutting-edge techniques. Dive deeper into our offerings.
Go to
DSG2/CDHF5 products
collection>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Adenovirus Grade | Adenovirus quantity |
| vGMAD001272 | Human DSG2 Adenovirus particle | Research Grade-In vitro | 1E+10PFU (1E+10pfu/ml×1ml) |
| 5E+10PFU (1E+10pfu/ml×5ml) | |||
| 1E+11PFU (1E+10pfu/ml×10ml) | |||
| Research Grade-In vivo | 1E+11PFU (1E+11pfu/ml×1ml) | ||
| GMP-like Grade | inquiry | ||
| GMP Grade | inquiry |
Product Description
| Catalog ID | vGMAD001272 |
| Gene Name | DSG2 |
| Accession Number | NM_001943.5 |
| Gene ID | 1829 |
| Species | Human |
| Product Type | Adenovirus particle (overexpression) |
| Insert Length | 3357 bp |
| Gene Alias | CDHF5,HDGC |
| Fluorescent Reporter | EGFP |
| Mammalian Cell Selection | Null |
| Fusion Tag | HA (C-Terminal) |
| Promoter | EF1 |
| Resistance | Kanamycin |
| ORF Nucleotide Sequence | ATGGCGCGGAGCCCGGGACGCGCGTACGCCCTGCTGCTTCTCCTGATCTGCTTTAACGTTGGAAGTGGACTTCACTTACAGGTCTTAAGCACAAGAAATGAAAATAAGCTGCTTCCTAAACATCCTCATTTAGTGCGGCAAAAGCGCGCCTGGATCACCGCCCCCGTGGCTCTTCGGGAGGGAGAGGATCTGTCCAAGAAGAATCCAATTGCCAAGATACATTCTGATCTTGCAGAAGAAAGAGGACTCAAAATTACTTACAAATACACTGGAAAAGGGATTACAGAGCCACCTTTTGGTATATTTGTCTTTAACAAAGATACTGGAGAACTGAATGTTACCAGCATTCTTGATCGAGAAGAAACACCATTTTTTCTGCTAACAGGTTACGCTTTGGATGCAAGAGGAAACAATGTAGAGAAACCCTTAGAGCTACGCATTAAGGTTCTTGATATCAATGACAACGAACCAGTGTTCACACAGGATGTCTTTGTTGGGTCTGTTGAAGAGTTGAGTGCAGCACATACTCTTGTGATGAAAATCAATGCAACAGATGCAGATGAGCCCAATACCCTGAATTCGAAAATTTCCTATAGAATCGTATCTCTGGAGCCTGCTTATCCTCCAGTGTTCTACCTAAATAAAGATACAGGAGAGATTTATACAACCAGTGTTACCTTGGACAGAGAGGAACACAGCAGCTACACTTTGACAGTAGAAGCAAGAGATGGCAATGGAGAAGTTACAGACAAACCTGTAAAACAAGCTCAAGTTCAGATTCGTATTTTGGATGTCAATGACAATATACCTGTAGTAGAAAATAAAGTGCTTGAAGGGATGGTTGAAGAAAATCAAGTCAACGTAGAAGTTACGCGCATAAAAGTGTTCGATGCAGATGAAATAGGTTCTGATAATTGGCTGGCAAATTTTACATTTGCATCAGGAAATGAAGGAGGTTATTTCCACATAGAAACAGATGCTCAAACTAACGAAGGAATTGTGACCCTTATTAAGGAAGTAGATTATGAAGAAATGAAGAATCTTGACTTCAGTGTTATTGTCGCTAATAAAGCAGCTTTTCACAAGTCGATTAGGAGTAAATACAAGCCTACACCCATTCCCATCAAGGTCAAAGTGAAAAATGTGAAAGAAGGCATTCATTTTAAAAGCAGCGTCATCTCAATTTATGTTAGCGAGAGCATGGATAGATCAAGCAAAGGCCAAATAATTGGAAATTTTCAAGCTTTTGATGAGGACACTGGACTACCAGCCCATGCAAGATATGTAAAATTAGAAGATAGAGATAATTGGATCTCTGTGGATTCTGTCACATCTGAAATTAAACTTGCAAAACTTCCTGATTTTGAATCTAGATATGTTCAAAATGGCACATACACTGTAAAGATTGTGGCCATATCAGAAGATTATCCTAGAAAAACCATCACTGGCACAGTCCTTATCAATGTTGAAGACATCAACGACAACTGTCCCACACTGATAGAGCCTGTGCAGACAATCTGTCACGATGCAGAGTATGTGAATGTTACTGCAGAGGACCTGGATGGACACCCAAACAGTGGCCCTTTCAGTTTCTCCGTCATTGACAAACCACCTGGCATGGCAGAAAAATGGAAAATAGCACGCCAAGAAAGTACCAGTGTGCTGCTGCAACAAAGTGAGAAAAAGCTTGGGAGAAGTGAAATTCAGTTCCTGATTTCAGACAATCAGGGTTTTAGTTGTCCTGAAAAGCAGGTCCTTACACTCACAGTTTGTGAGTGTCTGCATGGCAGCGGCTGCAGGGAAGCACAGCATGACTCCTATGTGGGCCTGGGACCCGCAGCAATTGCGCTCATGATTTTGGCCTTTCTGCTCCTGCTATTGGTACCACTTTTACTGCTGATGTGCCATTGCGGAAAGGGCGCCAAAGGCTTTACCCCCATACCTGGCACCATAGAGATGCTGCATCCTTGGAATAATGAAGGAGCACCACCTGAAGACAAGGTGGTGCCATCATTTCTGCCAGTGGATCAAGGGGGCAGTCTAGTAGGAAGAAATGGAGTAGGAGGTATGGCCAAGGAAGCCACGATGAAAGGAAGTAGCTCTGCTTCCATTGTCAAAGGGCAACATGAGATGTCCGAGATGGATGGAAGGTGGGAAGAACACAGAAGCCTGCTTTCTGGTAGAGCTACCCAGTTTACAGGGGCCACAGGCGCTATCATGACCACTGAAACCACGAAGACCGCAAGGGCCACAGGGGCTTCCAGAGACATGGCCGGAGCTCAGGCAGCTGCTGTTGCACTGAACGAAGAATTCTTAAGAAATTATTTCACTGATAAAGCGGCCTCTTACACTGAGGAAGATGAAAATCACACAGCCAAAGATTGCCTTCTGGTTTATTCTCAGGAAGAAACTGAATCGCTGAATGCTTCTATTGGTTGTTGCAGTTTTATTGAAGGAGAGCTAGATGACCGCTTCTTAGATGATTTGGGACTTAAATTCAAGACACTAGCTGAAGTTTGCCTGGGTCAAAAAATAGATATAAATAAGGAAATTGAGCAGAGACAAAAACCTGCCACAGAAACAAGTATGAACACAGCTTCACATTCACTCTGTGAGCAAACTATGGTTAATTCAGAGAATACCTACTCCTCTGGCAGTAGCTTCCCAGTTCCAAAATCTTTGCAAGAAGCCAATGCAGAGAAAGTAACTCAGGAAATAGTCACTGAAAGATCTGTGTCTTCTAGGCAGGCGCAAAAGGTAGCTACACCTCTTCCTGACCCAATGGCTTCTAGAAATGTGATAGCAACAGAAACTTCCTATGTCACAGGGTCCACTATGCCACCAACCACTGTGATCCTGGGTCCTAGCCAGCCACAGAGCCTTATTGTGACAGAGAGGGTGTATGCTCCAGCTTCTACCTTGGTAGATCAGCCTTATGCTAATGAAGGTACAGTTGTGGTCACTGAAAGAGTAATACAGCCTCATGGGGGTGGATCGAATCCTCTGGAAGGCACTCAGCATCTTCAAGATGTACCTTACGTCATGGTGAGGGAAAGAGAGAGCTTCCTTGCCCCCAGCTCAGGTGTGCAGCCTACTCTGGCCATGCCTAATATAGCAGTAGGACAGAATGTGACAGTGACAGAAAGAGTTCTAGCACCTGCTTCCACTCTGCAATCCAGTTACCAGATTCCCACTGAAAATTCTATGACGGCTAGGAACACCACGGTGTCTGGAGCTGGAGTCCCTGGCCCTCTGCCAGATTTTGGTTTAGAGGAATCTGGTCATTCTAATTCTACCATAACCACATCTTCCACCAGAGTTACCAAGCATAGCACTGTACAGCATTCTTACTCCTAA |
| ORF Protein Sequence | MARSPGRAYALLLLLICFNVGSGLHLQVLSTRNENKLLPKHPHLVRQKRAWITAPVALREGEDLSKKNPIAKIHSDLAEERGLKITYKYTGKGITEPPFGIFVFNKDTGELNVTSILDREETPFFLLTGYALDARGNNVEKPLELRIKVLDINDNEPVFTQDVFVGSVEELSAAHTLVMKINATDADEPNTLNSKISYRIVSLEPAYPPVFYLNKDTGEIYTTSVTLDREEHSSYTLTVEARDGNGEVTDKPVKQAQVQIRILDVNDNIPVVENKVLEGMVEENQVNVEVTRIKVFDADEIGSDNWLANFTFASGNEGGYFHIETDAQTNEGIVTLIKEVDYEEMKNLDFSVIVANKAAFHKSIRSKYKPTPIPIKVKVKNVKEGIHFKSSVISIYVSESMDRSSKGQIIGNFQAFDEDTGLPAHARYVKLEDRDNWISVDSVTSEIKLAKLPDFESRYVQNGTYTVKIVAISEDYPRKTITGTVLINVEDINDNCPTLIEPVQTICHDAEYVNVTAEDLDGHPNSGPFSFSVIDKPPGMAEKWKIARQESTSVLLQQSEKKLGRSEIQFLISDNQGFSCPEKQVLTLTVCECLHGSGCREAQHDSYVGLGPAAIALMILAFLLLLLVPLLLLMCHCGKGAKGFTPIPGTIEMLHPWNNEGAPPEDKVVPSFLPVDQGGSLVGRNGVGGMAKEATMKGSSSASIVKGQHEMSEMDGRWEEHRSLLSGRATQFTGATGAIMTTETTKTARATGASRDMAGAQAAAVALNEEFLRNYFTDKAASYTEEDENHTAKDCLLVYSQEETESLNASIGCCSFIEGELDDRFLDDLGLKFKTLAEVCLGQKIDINKEIEQRQKPATETSMNTASHSLCEQTMVNSENTYSSGSSFPVPKSLQEANAEKVTQEIVTERSVSSRQAQKVATPLPDPMASRNVIATETSYVTGSTMPPTTVILGPSQPQSLIVTERVYAPASTLVDQPYANEGTVVVTERVIQPHGGGSNPLEGTQHLQDVPYVMVRERESFLAPSSGVQPTLAMPNIAVGQNVTVTERVLAPASTLQSSYQIPTENSMTARNTTVSGAGVPGPLPDFGLEESGHSNSTITTSSTRVTKHSTVQHSYS |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
|---|---|---|
| Target Antibody | GM-Tg-g-MP0379-Ab | Anti-DSG2/ CDHF5/ HDGC monoclonal antibody |
| Target Antigen | GM-Tg-g-MP0379-Ag | DSG2 VLP (virus-like particle) |
| ORF Viral Vector | pGMAD001272 | Human DSG2 Adenovirus plasmid |
| ORF Viral Vector | pGMAAV001325 | Human DSG2 Adeno-associate virus(AAV) plasmid |
| ORF Viral Vector | pGMAAV001955 | Human DSG2 Adeno-associate virus(AAV) plasmid |
| ORF Viral Vector | vGMAD001272 | Human DSG2 Adenovirus particle |
| ORF Viral Vector | vGMAAV001325 | Human DSG2 Adeno-associate virus(AAV) particle |
| ORF Viral Vector | vGMAAV001955 | Human DSG2 Adeno-associate virus(AAV) particle |
Target information
| Target ID | GM-MP0379 |
| Target Name | DSG2 |
|
Gene Group Identifier (Target Gene ID in Homo species) |
1829 |
| Gene ID |
100066038 (Equus caballus), 101088118 (Felis catus), 13511 (Mus musculus), 1829 (Homo sapiens) 307562 (Rattus norvegicus), 490500 (Canis lupus familiaris), 508151 (Bos taurus), 705805 (Macaca mulatta) |
| Gene Symbols & Synonyms | DSG2,Dsg2,D18Ertd293e,HDGC,CDHF5 |
| Target Alternative Names | CDHF5,Cadherin family member 5,D18Ertd293e,DSG2,Desmoglein-2,Dsg2,HDGC |
| Uniprot Accession |
O55111,Q14126
Additional SwissProt Accessions: O55111,Q14126 |
| Uniprot Entry Name | |
| Protein Sub-location | Transmembrane Protein |
| Category | |
| Disease | Prostate Cancer, Heart failure, Mucocutaneous lymph node syndrome [Kawasaki] |
| Disease from KEGG | Arrhythmogenic right ventricular cardiomyopathy |
| Gene Ensembl | ENSECAG00000013616, ENSMUSG00000044393, ENSG00000046604, ENSCAFG00845010678, ENSBTAG00000021923, ENSMMUG00000021095 |
| Target Classification |
About GMVC

GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.


